论文部分内容阅读
作者对79例乳腺癌患者进行一种新的肿瘤表面抗原CA15-3放射免疫测定,并与对照组进行对比分析,指出测定乳腺癌患者CA15-3的临床意义。测定结果:(1)正常对照组中79例正常女性的CA15-3值为9.8±4.4U/ml,此与年龄组无关,正常值为20U/ml,超过该值者为阳性,对照组中仅3例阳性,占3.8%。(2)原发性乳腺癌47例,其CA15-3值为24.1±59.6U/ml,无远处转移的44例,CA 15-3值为15.8±12.2U/ml,二者与正常女性相比差异显著(P<0.05)。Ⅰ期者其值为13.9±8.4U/ml,比
The authors performed a new radioimmunoassay for tumor surface antigen CA15-3 in 79 cases of breast cancer and compared them with the control group, pointing out the clinical significance of the determination of CA15-3 in breast cancer patients. Measurement results: (1) The CA15-3 value of 79 normal women in the normal control group was 9.8±4.4 U/ml, which was not related to the age group, and the normal value was 20 U/ml. Those who surpassed this value were positive and in the control group. Only 3 cases were positive, accounting for 3.8%. (2) In 47 cases of primary breast cancer, the CA15-3 value was 24.1±59.6 U/ml, there was no distant metastasis in 44 cases, and the CA 15-3 value was 15.8±12.2 U/ml, both with normal women. The difference was significant (P<0.05). In phase I, the value was 13.9±8.4 U/ml,